London Stock Exchange welcomes Arecor to AIM

London Stock Exchange today welcomes Arecor Therapeutics (“Arecor”) as it begins trading on AIM under the ticker “AREC” having successfully raised £20 million in an oversubscribed raise, giving a market capitalisation at IPO of £62.5 million.

Arecor is a globally focused biopharmaceutical company that is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products.  By applying its innovative proprietary formulation technology platform, Arestat™, Arecor is developing a portfolio of proprietary products and working with leading pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies, supported by an extensive patent portfolio.

The Arestat™ technology, in combination with the extensive know-how of stability requirements, development processes and regulatory requirements, offers a series of formulation options that have been specifically designed to overcome the challenges associated with delivering enhanced pharmaceutical products via reformulation. 

Arecor proprietary product portfolio is currently focused on diabetes and specialty hospital care. For partners, it develops novel enhanced formulations of their biological products that include biosimilars, biological products and vaccines. 

The proceeds will be used to progress the Company’s lead diabetes products, develop and expand its pipeline of specialty hospital Ready-To-Use and Ready-To-Administer products and build the team, as well as bolster working capital and strengthen the balance sheet.

Sarah Howell, Chief Executive Officer of Arecor, said: “Today represents an important milestone for Arecor and we are delighted to be listing on AIM.  This IPO will allow us to continue to grow the business through the development of our own proprietary diabetes and specialty hospital products whilst creating further value through our technology licensing partnerships. We were delighted by the support and interest we received during this transaction which is testament to the potential of our innovative proprietary formulation technology platform, Arestat™. I would like to take this opportunity to thank our new and existing shareholders for their support and we are looking forward to embarking on this next exciting chapter in the Company’s development.”

Andrew Richards, Chairman of Arecor, commented: “Arecor’s technology and expertise has been validated through multiple partnerships with major pharmaceutical and biotechnology companies. The Company also has a balanced business model that offers the potential for significant returns associated with successful drug development but with reduced development risk through development of existing approved therapeutics products and partnering. As someone who has always championed the London market and has supported UK life-science companies to IPO in London I am very pleased Arecor has chosen to list on AIM. Led by a strong team and Board, Arecor has the potential to become a significant UK biopharmaceutical company and deliver benefits to patients and clinicians.” 

Advisers to the IPO: 

Panmure Gordon (UK) Limited, Nominated Advisor and Sole Broker to the Company 
Covington & Burling LLP, Legal Advisers
Grant Thornton, Reporting Accountant
Consilium Communications, Financial PR Advisers

Quick facts

Track
Market: AIM
Instrument market cap (£m)
105.77
Listing/Admission to trading
03 Jun 2021
Looking for new and recent issues?

More recent

31.36
London Stock Exchange welcomes The Arab Federation of Capital Markets.

  General Overview 

The Arab Federation of Capital Markets (AFCM) is the Arab industry group for Exchanges and Clearing houses, and Financial Institutions around the Arab regions. It was established in 1978 to be the guiding body for the Arab Stock Exchanges, under the recommendation of the Arab Central Ban

Learn more
121.96
London Stock Exchange welcomes EnSilica plc to AIM

EnSilica is a designer and supplier of mixed signal ASICs (Application Specific Integrated Circuit). ASICs are Integrated Circuits or semiconductor chips developed for a particular use or product rather than for general purpose usage.  ASICs help differentiate products through optimised hardware making products smaller, faster, lower power, improved security, add

Learn more
60.84
London Stock Exchange Group welcomes The Future Investment Initiative Institute, celebrating the launch of the FII regional summit “Inclusive ESG for Emerging Markets”

The Future Investment Initiative (FII) Institute is a new global nonprofit foundation with an investment arm and one agenda: Impact on Humanity. Global, inclusive and committed to ESG principles, the FII Institute fosters great minds from around the world and turn ideas into real-world solutions in four critical areas: AI and Robotics, Education, Healthcare and Sustainability. The FII Institute

Learn more
European Assets Trust PLC celebrates 50 years.

This year, European Assets Trust PLC celebrates its fiftieth anniversary since launch in May 1972. The Company was created in 1972 following the acquisition of a Dutch investment company ‘Mijbeb NV’ by a consortium of United Kingdom institutional investors and the appointment of a predecessor of BMO Investment Business Limited as its Manager.

Initially the Company was listed solely on

Learn more